Pharma Focus Asia

Emergent BioSolutions Invests US$75 million in New Manufacturing Unit


Emergent BioSolutions has announced US$75 million investment plan to expand viral vector and gene therapy capabilities in its facility at Canton, Massachusetts.


This investment is part of the company’s bid to strengthen its Contract Development and Manufacturing (CDMO) capabilities by expanding viral and gene therapies.

The new facility mainly focuses on the manufacturing and expansion of live viral vaccines including smallpox vaccines. In addition, viral vector and gene therapy capabilities will increase campus footprint and build advanced therapy capability.

The facility includes state-of-the-art and multi-suite operation up to 1000L scale. With the addition of advanced therapy scale to the Canton facility, the company will build upon its biologics platforms complement its existing smallpox vaccine capabilities.


NameEmergent BioSolutions
TypeNew Construction
BudgetUS$75 million
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?